E MERCK EXPECTS PICK-UP IN 1994

5 June 1994

A marked recovery in the economy in 1994 for the Darmstadt-based pharmaceutical company E Merck is indicated, according to the chairman Joachim Langmann.

Merck's key business indicators have improved in the last few months, with sales up 8.1% to 1.86 billion Deutschemarks ($1.1 billion) in the January-April period. First-quarter profits have almost doubled over the same 1993 quarter.

Mr Langmann expects total 1994 sales to rise from 5.3 billion marks to 6 billion marks, with profits at 4%-5% of sales. Merck is to continue measures to improve efficiency, given that the sharp downturn last year will not be completely offset. Further jobs will go in Germany.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight